• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session

    9/20/22 12:41:48 PM ET
    $ADXN
    $AKA
    $ARAV
    $BCAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $ADXN alert in real time by email

    Gainers

    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) gained 47.7% to $3.6493 after the company announced the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) shares gained 25.8% to $6.92. BYND Cannasoft shares jumped over 32% on Monday after the company announced it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments for $28 million in stock.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) jumped 24.7% to $1.3299 after the company announced Bonum Health, a subsidiary, signed a Telemedicine Services Distribution Deal with Wakefern Food, to deploy telemedicine services throughout ShopRite pharmacy-led locations in New Jersey, New York, Pennsylvania, Connecticut and Maryland.
    • GigaCloud Technology Inc. (NASDAQ:GCT) gained 19.8% to $15.90.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) shares gained 19.4% to $2.89 after gaining over 4% on Monday.
    • a.k.a. Brands Holding Corp. (NYSE:AKA) jumped 18.8% to $1.7112.
    • SeqLL Inc. (NASDAQ:SQL) gained 16.1% to $0.9333.
    • Renovacor, Inc. (NYSE:RCOR) jumped 14.7% to $2.1794. Rocket Pharmaceuticals agreed to acquire Renovacor in an all-stock transaction for an implied value of approximately $2.60 per share.
    • Amprius Technologies, Inc. (NYSE:AMPX) rose 13.5% to $6.70.
    • Studio City International Holdings Limited (NYSE:MSC) gained 13.5% to $2.3150.
    • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 13% to $1.90 after gaining 5% on Monday.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) rose 12.2% to $0.96 after declining around 9% on Monday.
    • O2Micro International Limited (NASDAQ:OIIM) rose 10.2% to $3.25 after the company announced receipt of a revised preliminary non-binding proposal to acquire the company.
    • Alaunos Therapeutics, Inc. (NASDAQ:TCRT) gained 10% to $2.7301.
    • Melco Resorts & Entertainment Limited (NASDAQ:MLCO) rose 9.7% to $6.39.
    • AEA-Bridges Impact Corp. (NYSE:IMPX) gained 9.3% to $10.80.
    • Innoviz Technologies Ltd. (NASDAQ:INVZ) gained 8.9% to $6.03 after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $22 price target.
    • Cognex Corporation (NASDAQ:CGNX) rose 8.3% to $45.17 as the company boosted its guidance for the third quarter.
    • bluebird bio, Inc. (NASDAQ:BLUE) jumped 8% to $6.41. Raymond James maintained bluebird bio with an Outperform and raised the price target from $8 to $10.
    • RLX Technology Inc. (NYSE:RLX) gained 6.8% to $1.25.
    • Oxford Industries, Inc. (NYSE:OXM) climbed 6.8% to $96.11. Oxford Industries completed the acquisition of Johnny Was, a California-based affordable luxury apparel brand, for $270 million. Piper Sandler maintained Oxford Industries with an Overweight and raised the price target from $130 to $135.
    • Change Healthcare Inc. (NASDAQ:CHNG) rose 6.7% to $27.18 after a U.S. judge denied the Justice Department's request to stop UnitedHealth's $13 billion buyout deal for Change Healthcare.
    • Lyft, Inc. (NASDAQ:LYFT) gained 5.6% to $17.16.


    Losers

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) fell 74.5% to $0.5079 after the company priced a 10 million share public offering at $0.50 per share. Also, HC Wainwright & Co downgraded the stock from Buy to Neutral.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) shares tumbled 58.9% to $2.87 after dropping 11% on Monday.
    • Cosmos Holdings Inc. (NASDAQ:COSM) dropped 38.6% to $0.2271.
    • Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) dipped 24.6% to $0.7982 as the U.S. FDA staff raised concerns over the safety of the company’s experimental cancer drug and questioned the benefits it provided over existing therapies.
    • Tellurian Inc. (NYSE:TELL) fell 22.5% to $3.0231.
    • Winc, Inc. (NYSE:WBEV) fell 20.5% to $0.7154 after jumping around 27% on Monday.
    • FOXO Technologies Inc. (NYSE:FOXO) dropped 16.8% to $2.0799.
    • Ventoux CCM Acquisition Corp. (NASDAQ:VTAQ) fell 16.3% to $5.90 after climbing around 55% on Monday.
    • MicroCloud Hologram Inc (NASDAQ:HOLO) dropped 14.9% to $2.5101.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) fell 14.7% to $0.1439. Esports Entertainment recently priced a 30 million share plus warrant public offering at $0.25 per share plus warrant.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) fell 14% to $0.1333.
    • Sotera Health Company (NASDAQ:SHC) fell 13.7% to $8.50
    • CF Acquisition Corp. VI (NASDAQ:RUM) dipped 12.8% to $14.63.
    • Dawson Geophysical Company (NASDAQ:DWSN) fell 12.3% to $1.91.
    • Rockley Photonics Holdings Limited (NYSE:RKLY) dropped 11.8% to $1.0050.
    • Vericity, Inc. (NASDAQ:VERY) fell 9.6% to $6.60.
    • Ford Motor Company (NYSE:F) fell 9.1% to $13.57 after the company previewed the effect of parts shortages on the company in the third-quarter and said inflation-related supplier costs during the third quarter will run about $1.0 billion higher than originally expected. The company also projects to have about 40,000 to 45,000 vehicles in inventory at end of third quarter lacking certain parts presently in short supply.
    • Vor Biopharma Inc. (NASDAQ:VOR) dropped 7.2% to $4.27.
    • Aravive, Inc. (NASDAQ:ARAV) fell 7.1% to $0.9473.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) fell 6.4% to $1.15. Clovis Oncology recently submitted applications for Rubraca label expansion in the US and European Union as first-line maintenance treatment in women with advanced ovarian cancer.
    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AKA
    $ARAV
    $BCAN

    CompanyDatePrice TargetRatingAnalyst
    Melco Resorts & Entertainment Limited
    $MLCO
    2/17/2026$9.50Neutral → Buy
    UBS
    Cognex Corporation
    $CGNX
    2/17/2026$68.00Hold → Buy
    HSBC Securities
    Melco Resorts & Entertainment Limited
    $MLCO
    1/16/2026$7.70Overweight → Neutral
    Analyst
    Oxford Industries Inc.
    $OXM
    1/13/2026$35.00 → $40.00Market Perform
    Telsey Advisory Group
    Vor Biopharma Inc.
    $VOR
    1/9/2026$50.00Buy
    Citigroup
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    Ford Motor Company
    $F
    1/8/2026$16.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair and Chair Ford William Clay Jr received a gift of 2,750 units of Class B Stock, bought $1,934,450 worth of Class B Stock (140,000 units at $13.82) and acquired 668,326 shares, increasing direct ownership by 141% to 995,908 units (SEC Form 4)

    4 - FORD MOTOR CO (0000037996) (Issuer)

    2/23/26 4:30:27 PM ET
    $F
    Auto Manufacturing
    Industrials

    Chief Executive Officer Risher John David bought $100,179 worth of shares (7,490 units at $13.38), increasing direct ownership by 0.07% to 11,481,792 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/18/26 4:10:21 PM ET
    $LYFT
    Real Estate

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Melco Resorts & Entertainment upgraded by UBS with a new price target

    UBS upgraded Melco Resorts & Entertainment from Neutral to Buy and set a new price target of $9.50

    2/17/26 8:04:32 AM ET
    $MLCO
    Hotels/Resorts
    Consumer Discretionary

    Cognex upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Cognex from Hold to Buy and set a new price target of $68.00

    2/17/26 8:01:33 AM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    Melco Resorts & Entertainment downgraded by Analyst with a new price target

    Analyst downgraded Melco Resorts & Entertainment from Overweight to Neutral and set a new price target of $7.70

    1/16/26 8:31:45 AM ET
    $MLCO
    Hotels/Resorts
    Consumer Discretionary

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    a.k.a. Brands Holding Corp. Announces Participation in the UBS Global Consumer and Retail Conference

    a.k.a. Brands Holding Corp. (NYSE:AKA) (the "Company"), a portfolio of next generation fashion brands, today announced that the Company is scheduled to participate in a fireside chat at the UBS Global Consumer and Retail Conference on Wednesday, March 11, 2026, at 4:00 pm Eastern Time. Chief Executive Officer, Ciaran Long, will participate in the fireside chat. The fireside chat will be webcast live over the internet and can be accessed on the Company's Investor Relations website, https://ir.aka-brands.com. An online archive will be available on that site following the fireside chat. About a.k.a. Brands a.k.a. Brands maintains a portfolio of global fashion brands, Princess Polly, Cult

    2/25/26 8:00:00 AM ET
    $AKA
    Catalog/Specialty Distribution
    Consumer Discretionary

    Innoviz Reports Fourth Quarter and Full Year 2025 Results

    FY 2025 Revenues of $55.1 million more than doubled year over year, with record gross marginsSelected by Daimler Truck and Torc Robotics for series production of L4 Class 8 autonomous trucks, ongoing progress in L3 and L4 automotive programs with Mobileye, VW and othersIntroduced InnovizThree for behind-the-windshield deployment, featuring smaller size, lower power consumption, lower cost, and embedded sensor fusionStrong traction with InnovizSMART and InnovizSMARTer for Physical AI, non-automotive applications; momentum in perimeter security deploymentsTEL AVIV, Israel, Feb. 25, 2026 /PRNewswire/ -- Innoviz Technologies Ltd. (NASDAQ:INVZ) (the "Company" or "Innoviz"), a leading Tier-1 direc

    2/25/26 7:00:00 AM ET
    $INVZ
    Auto Parts:O.E.M.
    Consumer Discretionary

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Llewellyn Lindsay Catherine covered exercise/tax liability with 51,677 shares, decreasing direct ownership by 7% to 720,511 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:24:19 PM ET
    $LYFT
    Real Estate

    CHIEF ACCOUNTING OFFICER Hope Stephen W. covered exercise/tax liability with 6,055 shares, decreasing direct ownership by 2% to 305,854 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:22:10 PM ET
    $LYFT
    Real Estate

    CHIEF FINANCIAL OFFICER Brewer Erin covered exercise/tax liability with 88,880 shares, gifted 76,190 shares and received a gift of 76,190 shares, decreasing direct ownership by 14% to 1,014,851 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:20:19 PM ET
    $LYFT
    Real Estate

    $ADXN
    $AKA
    $ARAV
    $BCAN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKA
    $ARAV
    $BCAN
    SEC Filings

    View All

    SEC Form 6-K filed by Innoviz Technologies Ltd.

    6-K - Innoviz Technologies Ltd. (0001835654) (Filer)

    2/25/26 8:31:21 AM ET
    $INVZ
    Auto Parts:O.E.M.
    Consumer Discretionary

    SEC Form 10-K filed by Sotera Health Company

    10-K - Sotera Health Co (0001822479) (Filer)

    2/24/26 4:15:21 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Sotera Health Co (0001822479) (Filer)

    2/24/26 7:14:33 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cognex Appoints Sami Atiya and Chris Donato to Board of Directors

    NATICK, Mass., Feb. 17, 2026 /PRNewswire/ -- Cognex Corporation (NASDAQ:CGNX), ("Cognex"), the global technology leader in industrial machine vision, today announced the appointments of Dr. Sami Atiya and Mr. Chris Donato to Cognex's Board of Directors (the "Board"), effective March 2, 2026.  "We are excited to welcome Sami and Chris to our Board," said Matt Moschner, President and CEO. "We remain focused on our strategic objectives of becoming the leading provider of AI technology for industrial machine vision, delivering the best customer experience in our industry and doublin

    2/17/26 8:00:00 AM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    $ADXN
    $AKA
    $ARAV
    $BCAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Innoviz Technologies Ltd.

    SC 13G/A - Innoviz Technologies Ltd. (0001835654) (Subject)

    11/14/24 8:27:58 PM ET
    $INVZ
    Auto Parts:O.E.M.
    Consumer Discretionary